Daiichi Sankyo Company, Limited Logo

Daiichi Sankyo Company, Limited

DSNKY

(1.8)
Stock Price

28,21 USD

7.28% ROA

15.13% ROE

40.67x PER

Market Cap.

9.286.559.073.599,00 USD

5.91% DER

0% Yield

14.24% NPM

Daiichi Sankyo Company, Limited Stock Analysis

Daiichi Sankyo Company, Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Daiichi Sankyo Company, Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (12%), which means it has a small amount of debt compared to the ownership it holds

2 ROE

The stock's ROE falls within an average range (7.63%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (5.37%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

4 Assets Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

5 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

6 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (44.332), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

7 PBV

The stock's high Price-to-Book Value (P/BV) ratio (5.45x) suggests it's overvalued, potentially making it an expensive investment.

8 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

10 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

11 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

Daiichi Sankyo Company, Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Daiichi Sankyo Company, Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Daiichi Sankyo Company, Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Daiichi Sankyo Company, Limited Revenue
Year Revenue Growth
2000 589.732.000.000
2001 545.072.000.000 -8.19%
2002 548.893.000.000 0.7%
2003 569.927.000.000 3.69%
2004 596.345.000.000 4.43%
2005 587.830.000.000 -1.45%
2006 925.918.000.000 36.51%
2007 929.507.000.000 0.39%
2008 880.120.000.000 -5.61%
2009 842.147.000.000 -4.51%
2010 952.105.000.000 11.55%
2011 967.365.000.000 1.58%
2012 938.677.000.000 -3.06%
2013 997.852.000.000 5.93%
2014 1.118.241.000.000 10.77%
2015 919.372.000.000 -21.63%
2016 986.446.000.000 6.8%
2017 955.124.000.000 -3.28%
2018 960.195.000.000 0.53%
2019 929.717.000.000 -3.28%
2020 981.793.000.000 5.3%
2021 962.516.000.000 -2%
2022 1.044.892.000.000 7.88%
2023 1.502.032.000.000 30.43%
2023 1.278.478.000.000 -17.49%
2024 1.601.688.000.000 20.18%
2025 1.744.700.000.000 8.2%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Daiichi Sankyo Company, Limited Research and Development Expenses
Year Research and Development Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 158.716.000.000 100%
2007 170.662.000.000 7%
2008 163.472.000.000 -4.4%
2009 184.539.000.000 11.42%
2010 196.802.000.000 6.23%
2011 194.330.000.000 -1.27%
2012 185.052.000.000 -5.01%
2013 183.047.000.000 -1.1%
2014 191.212.000.000 4.27%
2015 190.666.000.000 -0.29%
2016 208.656.000.000 8.62%
2017 214.347.000.000 2.66%
2018 236.046.000.000 9.19%
2019 203.711.000.000 -15.87%
2020 197.465.000.000 -3.16%
2021 227.353.000.000 13.15%
2022 260.228.000.000 12.63%
2023 355.756.000.000 26.85%
2023 341.570.000.000 -4.15%
2024 365.169.000.000 6.46%
2025 402.856.000.000 9.35%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Daiichi Sankyo Company, Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 212.235.000.000
2001 234.293.000.000 9.41%
2002 246.801.000.000 5.07%
2003 261.335.000.000 5.56%
2004 279.137.000.000 6.38%
2005 289.015.000.000 3.42%
2006 321.738.000.000 10.17%
2007 357.330.000.000 9.96%
2008 325.250.000.000 -9.86%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 413.187.000.000 100%
2015 331.195.000.000 -24.76%
2016 328.755.000.000 -0.74%
2017 302.475.000.000 -8.69%
2018 301.845.000.000 -0.21%
2019 277.695.000.000 -8.7%
2020 302.320.000.000 8.15%
2021 333.079.000.000 9.23%
2022 358.309.000.000 7.04%
2023 564.136.000.000 36.49%
2023 471.221.000.000 -19.72%
2024 636.997.000.000 26.02%
2025 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Daiichi Sankyo Company, Limited EBITDA
Year EBITDA Growth
2000 142.713.000.000
2001 87.790.000.000 -62.56%
2002 80.650.000.000 -8.85%
2003 105.693.000.000 23.69%
2004 123.703.000.000 14.56%
2005 114.114.000.000 -8.4%
2006 203.163.000.000 43.83%
2007 251.076.000.000 19.08%
2008 199.415.000.000 -25.91%
2009 636.000.000.000 68.65%
2010 300.320.000.000 -111.77%
2011 329.730.000.000 8.92%
2012 323.312.000.000 -1.99%
2013 149.050.000.000 -116.92%
2014 178.189.000.000 16.35%
2015 125.119.000.000 -42.42%
2016 179.722.000.000 30.38%
2017 142.871.000.000 -25.79%
2018 131.924.000.000 -8.3%
2019 137.910.000.000 4.34%
2020 201.588.000.000 31.59%
2021 134.261.000.000 -50.15%
2022 137.514.000.000 2.37%
2023 281.148.000.000 51.09%
2023 203.123.000.000 -38.41%
2024 250.235.000.000 18.83%
2025 438.380.000.000 42.92%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Daiichi Sankyo Company, Limited Gross Profit
Year Gross Profit Growth
2000 354.948.000.000
2001 322.083.000.000 -10.2%
2002 327.451.000.000 1.64%
2003 341.173.000.000 4.02%
2004 374.692.000.000 8.95%
2005 373.941.000.000 -0.2%
2006 635.182.000.000 41.13%
2007 664.306.000.000 4.38%
2008 645.549.000.000 -2.91%
2009 627.750.000.000 -2.84%
2010 674.074.000.000 6.87%
2011 685.688.000.000 1.69%
2012 670.068.000.000 -2.33%
2013 684.195.000.000 2.06%
2014 715.952.000.000 4.44%
2015 596.285.000.000 -20.07%
2016 667.824.000.000 10.71%
2017 605.751.000.000 -10.25%
2018 614.174.000.000 1.37%
2019 565.112.000.000 -8.68%
2020 638.587.000.000 11.51%
2021 624.227.000.000 -2.3%
2022 691.564.000.000 9.74%
2023 1.123.088.000.000 38.42%
2023 914.953.000.000 -22.75%
2024 1.181.795.000.000 22.58%
2025 1.364.504.000.000 13.39%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Daiichi Sankyo Company, Limited Net Profit
Year Net Profit Growth
2000 42.817.000.000
2001 42.478.000.000 -0.8%
2002 38.795.000.000 -9.49%
2003 33.845.000.000 -14.63%
2004 43.411.000.000 22.04%
2005 48.282.000.000 10.09%
2006 87.693.000.000 44.94%
2007 78.550.000.000 -11.64%
2008 97.660.000.000 19.57%
2009 -215.499.000.000 145.32%
2010 41.852.000.000 614.91%
2011 70.121.000.000 40.31%
2012 10.383.000.000 -575.34%
2013 66.621.000.000 84.41%
2014 60.943.000.000 -9.32%
2015 322.119.000.000 81.08%
2016 82.282.000.000 -291.48%
2017 53.466.000.000 -53.9%
2018 60.282.000.000 11.31%
2019 93.409.000.000 35.46%
2020 129.074.000.000 27.63%
2021 75.958.000.000 -69.93%
2022 66.972.000.000 -13.42%
2023 159.972.000.000 58.14%
2023 109.188.000.000 -46.51%
2024 200.731.000.000 45.6%
2025 341.532.000.000 41.23%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Daiichi Sankyo Company, Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 31
2001 31 0%
2002 29 -10.71%
2003 25 -12%
2004 33 21.88%
2005 37 13.51%
2006 40 5.13%
2007 36 -11.43%
2008 45 22.22%
2009 -101 144.55%
2010 20 631.58%
2011 33 42.42%
2012 5 -725%
2013 32 87.1%
2014 29 -10.71%
2015 153 81.58%
2016 40 -289.74%
2017 27 -50%
2018 30 13.33%
2019 48 37.5%
2020 66 27.27%
2021 39 -69.23%
2022 35 -14.71%
2023 83 59.04%
2023 57 -48.21%
2024 105 46.15%
2025 178 41.57%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Daiichi Sankyo Company, Limited Free Cashflow
Year Free Cashflow Growth
2003 42.245.000.000
2004 22.351.000.000 -89.01%
2005 66.982.000.000 66.63%
2006 84.174.000.000 20.42%
2007 63.478.000.000 -32.6%
2008 15.081.000.000 -320.91%
2009 33.781.000.000 55.36%
2010 99.078.000.000 65.9%
2011 105.007.000.000 5.65%
2012 28.869.000.000 -263.74%
2013 50.385.000.000 42.7%
2014 -17.210.000.000 392.77%
2015 48.146.000.000 135.75%
2016 97.860.000.000 50.8%
2017 83.272.000.000 -17.52%
2018 70.431.000.000 -18.23%
2019 25.420.000.000 -177.07%
2020 144.036.000.000 82.35%
2021 128.114.000.000 -12.43%
2022 62.544.000.000 -104.84%
2023 -40.889.000.000 252.96%
2023 47.148.000.000 186.72%
2024 476.467.000.000 90.1%
2025 -131.221.000.000 463.1%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Daiichi Sankyo Company, Limited Operating Cashflow
Year Operating Cashflow Growth
2003 69.167.000.000
2004 71.207.000.000 2.86%
2005 96.703.000.000 26.37%
2006 132.760.000.000 27.16%
2007 106.430.000.000 -24.74%
2008 66.667.000.000 -59.64%
2009 78.383.000.000 14.95%
2010 130.235.000.000 39.81%
2011 141.139.000.000 7.73%
2012 92.569.000.000 -52.47%
2013 129.247.000.000 28.38%
2014 37.304.000.000 -246.47%
2015 142.776.000.000 73.87%
2016 174.281.000.000 18.08%
2017 136.234.000.000 -27.93%
2018 108.439.000.000 -25.63%
2019 92.033.000.000 -17.83%
2020 196.601.000.000 53.19%
2021 192.207.000.000 -2.29%
2022 139.226.000.000 -38.05%
2023 -18.146.000.000 867.25%
2023 114.514.000.000 115.85%
2024 599.258.000.000 80.89%
2025 -110.042.000.000 644.57%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Daiichi Sankyo Company, Limited Capital Expenditure
Year Capital Expenditure Growth
2003 26.922.000.000
2004 48.856.000.000 44.9%
2005 29.721.000.000 -64.38%
2006 48.586.000.000 38.83%
2007 42.952.000.000 -13.12%
2008 51.586.000.000 16.74%
2009 44.602.000.000 -15.66%
2010 31.157.000.000 -43.15%
2011 36.132.000.000 13.77%
2012 63.700.000.000 43.28%
2013 78.862.000.000 19.23%
2014 54.514.000.000 -44.66%
2015 94.630.000.000 42.39%
2016 76.421.000.000 -23.83%
2017 52.962.000.000 -44.29%
2018 38.008.000.000 -39.34%
2019 66.613.000.000 42.94%
2020 52.565.000.000 -26.73%
2021 64.093.000.000 17.99%
2022 76.682.000.000 16.42%
2023 22.743.000.000 -237.17%
2023 67.366.000.000 66.24%
2024 122.791.000.000 45.14%
2025 21.179.000.000 -479.78%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Daiichi Sankyo Company, Limited Equity
Year Equity Growth
2000 615.011.000.000
2001 668.318.000.000 7.98%
2002 652.220.000.000 -2.47%
2003 667.088.000.000 2.23%
2004 691.437.000.000 3.52%
2005 726.021.000.000 4.76%
2006 1.249.139.000.000 41.88%
2007 1.272.148.000.000 1.81%
2008 1.244.513.000.000 -2.22%
2009 888.617.000.000 -40.05%
2010 889.508.000.000 0.1%
2011 887.702.000.000 -0.2%
2012 832.749.000.000 -6.6%
2013 915.743.000.000 9.06%
2014 1.007.527.000.000 9.11%
2015 1.307.041.000.000 22.92%
2016 1.233.521.000.000 -5.96%
2017 1.171.428.000.000 -5.3%
2018 1.133.040.000.000 -3.39%
2019 1.249.704.000.000 9.34%
2020 1.306.273.000.000 4.33%
2021 1.272.053.000.000 -2.69%
2022 1.350.872.000.000 5.83%
2023 1.445.854.000.000 6.57%
2023 1.594.002.000.000 9.29%
2024 1.688.602.000.000 5.6%
2025 1.720.849.000.000 1.87%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Daiichi Sankyo Company, Limited Assets
Year Assets Growth
2000 921.662.000.000
2001 964.902.000.000 4.48%
2002 916.305.000.000 -5.3%
2003 915.792.000.000 -0.06%
2004 927.244.000.000 1.24%
2005 976.230.000.000 5.02%
2006 1.596.127.000.000 38.84%
2007 1.636.835.000.000 2.49%
2008 1.487.889.000.000 -10.01%
2009 1.494.599.000.000 0.45%
2010 1.489.510.000.000 -0.34%
2011 1.480.240.000.000 -0.63%
2012 1.518.479.000.000 2.52%
2013 1.644.071.000.000 7.64%
2014 1.854.037.000.000 11.32%
2015 1.982.286.000.000 6.47%
2016 1.900.522.000.000 -4.3%
2017 1.914.979.000.000 0.75%
2018 1.897.754.000.000 -0.91%
2019 2.088.051.000.000 9.11%
2020 2.105.619.000.000 0.83%
2021 2.085.178.000.000 -0.98%
2022 2.221.402.000.000 6.13%
2023 2.508.889.000.000 11.46%
2023 2.649.101.000.000 5.29%
2024 3.461.135.000.000 23.46%
2025 3.437.132.000.000 -0.7%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Daiichi Sankyo Company, Limited Liabilities
Year Liabilities Growth
2000 0
2001 0 0%
2002 0 0%
2003 248.704.000.000 100%
2004 235.807.000.000 -5.47%
2005 250.209.000.000 5.76%
2006 346.988.000.000 27.89%
2007 364.687.000.000 4.85%
2008 242.998.000.000 -50.08%
2009 605.982.000.000 59.9%
2010 600.002.000.000 -1%
2011 592.538.000.000 -1.26%
2012 685.730.000.000 13.59%
2013 728.328.000.000 5.85%
2014 846.510.000.000 13.96%
2015 675.245.000.000 -25.36%
2016 667.001.000.000 -1.24%
2017 743.551.000.000 10.3%
2018 764.713.000.000 2.77%
2019 838.346.000.000 8.78%
2020 799.345.000.000 -4.88%
2021 813.125.000.000 1.69%
2022 870.530.000.000 6.59%
2023 1.063.035.000.000 18.11%
2023 1.055.099.000.000 -0.75%
2024 1.763.115.000.000 40.16%
2025 1.716.283.000.000 -2.73%

Daiichi Sankyo Company, Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
880.63
Net Income per Share
119.59
Price to Earning Ratio
40.67x
Price To Sales Ratio
5.5x
POCF Ratio
17.4
PFCF Ratio
22.22
Price to Book Ratio
5.42
EV to Sales
5.09
EV Over EBITDA
25.47
EV to Operating CashFlow
16.03
EV to FreeCashFlow
20.53
Earnings Yield
0.02
FreeCashFlow Yield
0.05
Market Cap
9.286,56 Bil.
Enterprise Value
8.582,92 Bil.
Graham Number
1554.7
Graham NetNet
-146.33

Income Statement Metrics

Net Income per Share
119.59
Income Quality
1.98
ROE
0.14
Return On Assets
0.08
Return On Capital Employed
0.11
Net Income per EBT
0.76
EBT Per Ebit
1.08
Ebit per Revenue
0.17
Effective Tax Rate
0.24

Margins

Sales, General, & Administrative to Revenue
0.3
Research & Developement to Revenue
0.23
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.76
Operating Profit Margin
0.17
Pretax Profit Margin
0.19
Net Profit Margin
0.14

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0.42
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
279.51
Free CashFlow per Share
218.19
Capex to Operating CashFlow
0.22
Capex to Revenue
0.07
Capex to Depreciation
1.89
Return on Invested Capital
0.11
Return on Tangible Assets
0.07
Days Sales Outstanding
117.8
Days Payables Outstanding
465.26
Days of Inventory on Hand
389.53
Receivables Turnover
3.1
Payables Turnover
0.78
Inventory Turnover
0.94
Capex per Share
61.32

Balance Sheet

Cash per Share
420,35
Book Value per Share
898,28
Tangible Book Value per Share
747.46
Shareholders Equity per Share
898.28
Interest Debt per Share
63.18
Debt to Equity
0.06
Debt to Assets
0.03
Net Debt to EBITDA
-2.09
Current Ratio
3.11
Tangible Asset Value
1.431,92 Bil.
Net Current Asset Value
345,56 Bil.
Invested Capital
2136454000000
Working Capital
1.399,18 Bil.
Intangibles to Total Assets
0.08
Average Receivables
464,19 Bil.
Average Payables
309,95 Bil.
Average Inventory
441404500000
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Daiichi Sankyo Company, Limited Dividends
Year Dividends Growth
2022 0
2023 0 0%

Daiichi Sankyo Company, Limited Profile

About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.

CEO
Mr. Sunao Manabe D.V.M., Ph.D
Employee
18.726
Address
3-5-1, Nihonbashi-honcho
Tokyo, 103-8426

Daiichi Sankyo Company, Limited Executives & BODs

Daiichi Sankyo Company, Limited Executives & BODs
# Name Age
1 Mr. Takashi Fukuoka D.V.M., Ph.D.
Senior Managing Executive Officer, Global Head of Corporate Strategy, Chief Strategy Officer & Director
70
2 Hiroto Kashiwase
Executive Officer & Head of Technology Division
70
3 Naoto Tsukaguchi
Gen. Counsel, Corporation Officer, Head of Global Legal & IP and Vice President of Leg. Aff. Dept.
70
4 Matt Allegrucci
Head of Global Compliance & Risk Management and Chief Compliance Officer
70
5 Tomohiro Kodama
General Manager of Finance & Accounting Department
70
6 Mr. Koji Ogawa
Managing Ex. Officer, Head of Corporate Planning & Mgt. and Chief Financial Officer
70
7 Mr. Hiroyuki Okuzawa
President, Chief Operating Officer & Representative Director
70
8 Kentaro Asakura
Vice President of Corporate Communications Department
70
9 Dr. Shoji Hirashima
Senior Managing Executive Officer, Head of Japan Business Unit & Representative Director
70
10 Mr. Sunao Manabe D.V.M., Ph.D.
Group Chief Executive Officer & Executive Chairperson
70

Daiichi Sankyo Company, Limited Competitors

Astellas Pharma Inc. Logo
Astellas Pharma Inc.

ALPMF

(2.2)
Grifols, S.A. Logo
Grifols, S.A.

GRFS

(0.5)
Roche Holding AG Logo
Roche Holding AG

RHHBY

(2.5)
Novartis AG Logo
Novartis AG

NVS

(2.0)
AstraZeneca PLC Logo
AstraZeneca PLC

AZN

(3.0)
GSK plc Logo
GSK plc

GSK

(2.2)
Sanofi Logo
Sanofi

SNY

(3.0)
Merck & Co., Inc. Logo
Merck & Co., Inc.

MRK

(2.2)
Amgen Inc. Logo
Amgen Inc.

AMGN

(3.2)
AbbVie Inc. Logo
AbbVie Inc.

ABBV

(2.0)
Johnson & Johnson Logo
Johnson & Johnson

JNJ

(2.8)